InvestorsHub Logo
Followers 467
Posts 26915
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 526

Monday, 09/30/2013 9:47:40 AM

Monday, September 30, 2013 9:47:40 AM

Post# of 535
8:40AM Transcept Pharma announced that it had received a communication from Retrophin stating that it owns 4.9% of the outstanding common stock of TSPT and seeking permission from the Board of Directors of Transcept to increase its ownership stake up to 15% (TSPT) 3.27 : Co announced that it had received a communication from Retrophin stating that it owns 4.9% of the outstanding common stock of Transcept and seeking permission from the Board of Directors of Transcept to increase its ownership stake up to 15% of the outstanding common stock of Transcept. After consultation with its financial and legal advisors, and after evaluating the Retrophin request in the context of the tax benefit preservation plan adopted on September 13, 2013, the Board of Directors of Transcept unanimously determined not to accede to this request.

During its deliberations, the Board of Directors of Transcept determined that granting the Retrophin request could jeopardize the value of the approximately $78 million in net operating loss carry forwards of Transcept. The tax benefit preservation plan was unanimously adopted by the Board to protect this asset for the benefit of all Transcept stockholders.